Comparative Pharmacology
Head-to-head clinical analysis: MOTPOLY XR versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTPOLY XR versus SUDAFED 12 HOUR.
MOTPOLY XR vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
Adults: 10 mg orally once daily, with or without food.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant